MONTPELLIER, France, June 01, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, will present at the 25 th BIO International Convention at The Boston Convention and Exhibition Center in Boston, Massachusetts, which takes place June 4- 7, 2018.
The company presentation will be given by chief executive officer of Sensorion, Nawal Ouzren, who will discuss the company’s clinical progress in the development of seliforant (formerly SENS-111) and SENS-401, the company’s on-going collaborations, and recent corporate milestones.
The details of the oral presentation are as follows:
| Session: | Company Presentations | ||
| Speaker: | Nawal Ouzren | ||
| Date & Time: | Monday, June 4 th at 2:45 PM – 2:58 EST | ||
| Location: | The Boston Convention and Exhibition Center, Theater 1 |
About BIO International Convention The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.
The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.
About Sensorion Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: seliforant, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.
Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, Inserm Transfert Initiative and institutional investors like Novalis Lifesciences.
| Contacts | |
| Sensorion | Investor Relations |
| Nawal Ouzren | LifeSci Advisors LLC |
| CEO | Chris Maggos, Managing Director, Europe |
| contact@sensorion-pharma.com | chris@lifesciadvisors.com |
| Tél : +33(0) 467 207 730 | Tél. : +41 79 367 6254 |
| Label : SENSORION | Press - Alize RP |
| ISIN : FR0012596468 | Caroline Carmagnol & Wendy Rigal |
| Mnemonic : ALSEN | sensorion@alizerp.com |
| Tel: +33 (0)1 44 54 36 66 | |
| US Media – LifeSci Public Relations | |
| Mike Tattory | |
| mtattory@lifescipublicrelations.com | |
| Tél: (646) 751-4362 |
Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16- 069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
